Skip to main content
Clinical Trials/JPRN-UMIN000009927
JPRN-UMIN000009927
Completed
Phase 2

Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma - Immunomoduratory activity for MM treated with lenalidomide

Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University0 sites33 target enrollmentFebruary 1, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
plasma cell myeloma
Sponsor
Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University
Enrollment
33
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2013
End Date
December 31, 2014
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) previously administered lenalidomide 2\) hypersensitive reaction for lenalidomide, thalidomide and dexamethazone 3\) non\-secretory myeloma, solitary plasmacytoma, plasmacell leukemia and POEMS syndrome 4\) CTCAE more than grade 3 neutropenia, thrombocytopenia 5\) HBsAg is positive 6\) HCV is positive, HIV is positive 7\) uncontrollable liver dysfunction, renal insufficiency, cardiac dysfunction, respiratory dysfunction, diabetus mellitus, hypertension and infection 8\) double cancer 9\) psychoneurotic disorder, depression state or history 10\) pregnant female, possible pregnancy or durling lactation 11\) pulomonary fibrosis and interstitial pneumonitis interstitial shadow on chest CT, even if no sympton 12\) physicians' decision

Outcomes

Primary Outcomes

Not specified

Similar Trials